drug · antibody
mogamulizumab
Marketedupdated 3mo agoby Kyowa Kirin Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 5 investigational indications.
targets
C-C chemokine receptor type 4
all catalysts(5)
approval · 5
Aug 8, 2018
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Jul 8, 2021
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Mar 30, 2022
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Jan 21, 2025
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Feb 19, 2026
approval
POTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approval
mogamulizumab
→
Trials studying mogamulizumab
- phase2A Study of VG712 in Patients With Mycosis Fungoides
- phase2Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
- phase1Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
- EP1Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
- phase2Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
- —Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
- phase4A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
- phase1Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that